Is there an upside for Endo International stock?
According to analysts' consensus price target of $5.00, Endo International has a forecasted upside of 112.8% from its current price of $2.35. Endo International has only been the subject of 2 research reports in the past 90 days. Endo International has received 921 “outperform” votes.
Where can I buy ENDP shares?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What does Endo International's P/E ratio mean?
The P/E ratio of Endo International is 8.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.20. The P/E ratio of Endo International is 8.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.10.
How much money does Endo make a year?
Endo International has a market capitalization of $549.13 million and generates $2.90 billion in revenue each year. The company earns $183.94 million in net income (profit) each year or $0.28 on an earnings per share basis. How many employees does Endo International have?
See more
Is ENDP stock a good buy?
Endo International plc - Hold Valuation metrics show that Endo International plc may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of ENDP, demonstrate its potential to outperform the market. It currently has a Growth Score of A.
Why is ENDP stock dropping?
The biggest reason for Endo's massive drop came when The Wall Street Journal reported the company was negotiating to restructure its more-than $8 billion in debt with its lenders and senior bondholders.
Who owns Endo Pharmaceuticals?
du Pont de Nemours and Company (DuPont) acquired Endo. In 1971, PERCOCET® was launched. In 1994, DuPont Merck reestablished Endo as a separate entity within the company. This entity was named Endo Laboratories L.L.C. and served as DuPont Merck's generic division.
Is Endo a public company?
Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system....Endo International.Typepublic liability companyNumber of employees2,910Websiteendo.com9 more rows
Does Endo Pharmaceuticals make Percocet?
Endo has a portfolio of thirteen branded products that includes established brands such as Percocet(R) and Percodan(R), opioid analgesics that treat moderate-to-severe pain.
Who bought out qualitest?
Endo PharmaceuticalsEndo Pharmaceuticals (Nasdaq: ENDP) announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately-held generics company in the U.S., for approximately $1.2 billion in cash.
Is ENDP stock a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last twelve months. There are...
Will Endo International's stock price go up in 2022?
4 brokerages have issued 12 month price objectives for Endo International's shares. Their forecasts range from $1.00 to $6.00. On average, they exp...
How has Endo International's stock price performed in 2022?
Endo International's stock was trading at $3.76 at the beginning of 2022. Since then, ENDP stock has decreased by 88.3% and is now trading at $0.44...
When is Endo International's next earnings date?
Endo International is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for E...
How were Endo International's earnings last quarter?
Endo International plc (NASDAQ:ENDP) posted its quarterly earnings data on Thursday, May, 5th. The company reported $0.66 EPS for the quarter, topp...
What guidance has Endo International issued on next quarter's earnings?
Endo International issued an update on its second quarter 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of -$0.17-...
Who are Endo International's key executives?
Endo International's management team includes the following people: Mr. Blaise A. Coleman , Pres, CEO & Director (Age 48, Pay $3.6M) Mr. Mark T....
What is Paul Campanelli's approval rating as Endo International's CEO?
25 employees have rated Endo International CEO Paul Campanelli on Glassdoor.com . Paul Campanelli has an approval rating of 86% among Endo Interna...
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Johnson & Johnson (JNJ) , Pfizer (PFE) , Eli Lilly and (LLY) , AbbVie (ABBV) , M...
When is Endo earnings call?
How much does Endo International make?
Endo International will be holding an earnings conference call on Friday, August 6th at 7:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "9749734".
Is Endo International a hold?
Endo International has a market capitalization of $1.17 billion and generates $2.90 billion in revenue each year. The company earns $183.94 million in net income (profit) each year or $2.87 on an earnings per share basis.
What is Endo Pharmaceuticals?
Wall Street analysts have given Endo International a "Hold" rating, but there may be better buying opportunities in the stock market . Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Endo International wasn't one of them.
Does Endo have a tax inversion?
Reported on 5/5/21. Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system.
NASDAQ
While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system. Wikipedia.
Environmental, Social, and Governance Rating
A specialty pharmaceutical company which is engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
